Login to Your Account

Strike 3 Finishes Nexavar's 'MISSION' in Phase III NSCLC

By Marie Powers
Staff Writer

Wednesday, May 23, 2012
To almost no one's surprise, another potential treatment in non-small-cell lung cancer (NSCLC) bit the dust as Nexavar (sorafenib) failed to meet the primary endpoint of improving overall survival (OS) in the Phase III MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial in patients with advanced relapsed or refractory nonsquamous disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription